Capricor: Positive Final Data in Phase 2 Duchenne Trial

 Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–

–Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction (p=0.002)–

–One-Year Results Demonstrated CAP-1002 Slowed Decline by 71% (Mid-level PUL v1.2)–

–CAP-1002 Significantly Improved Cardiac Function in Patients–

–Results Presented Today at World Muscle Society Annual Meeting in Late Breaking Oral Presentation–

–Principal Investigator Dr. Craig McDonald and Capricor Management Team will Host a Conference Call and Webcast Today at 8:30 a.m. ET–

Conference Call and Webcast Details
Capricor will host a conference call and webcast with slides today, September 24, 2021, at 8:30 a.m. ET to discuss the final data of the HOPE-2 study. To participate in the conference call, please dial 877-451-6152 (domestic) or 201-389-0879 (international) and reference the access code: 13723043

To participate via a webcast, please visit: http://public.viavid.com/index.php?id=146508 to view the slides. The webcast will be archived for approximately 30 days and will be available at http://capricor.com/news/events/.

https://finance.yahoo.com/news/capricor-therapeutics-announces-positive-final-110000669.html